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Introduction
Multiple myeloma (MM) is a B cell neoplasia, covering more than 10 % of total hematologic malignancies, which currently remains associated with a poor prognosis.
This pathology is mainly characterized by the accumulation of clonal malignant plasma cells in the bone marrow.
Several transduction pathways are constitutively activated in patients' primary multiple myeloma cells (MMC), particularly the Janus kinase (JAK)/ signal transducer and activator of transduction 3 (STAT3) (Bharti, et al 2004; Catlett-Falcone, et al 1999; De Vos, et al 2000) , the phosphatidylinositol-3 kinase (PI-3K)/Akt (Hsu, et al 2001) , the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) (Giuliani, et al 2004) , Wnt/βcatenin (Derksen, et al 2004) and the nuclear factor kappa-B (NF-κB) pathways (Berenson, et al 2001; Bharti, et al 2003; Bharti, et al 2004; Mitsiades, et al 2002a; Ni, et al 2001) . These pathways are activated by interactions with the microenvironment, plasma factors and a variety of MM growth factors (MGFs) . The main MGFs are interleukin (IL)-6 and IL-6 receptor (Gaillard, et al 1997; Zhang, et al 1992) , insulin-like growth factor-1 (IGF-1) (Ferlin, et al 2000) , B-cell activating factor (BAFF) / a proliferation-inducing ligand (APRIL) Moreaux, et al 2004) , hepatocyte growth factor (HGF) (Derksen, et al 2003) , the Wnt family (Derksen, et al 2004) , the epidermal growth factor (EGF) family Mahtouk, et al 2005; Mahtouk, et al 2004) , IL-10 (Gu, et al 1996) , IFN-alpha (Ferlin-Bezombes, et al 1998) , IL-15 (HjorthHansen, et al 1999) and IL-21 (Brenne, et al 2002) . Using human myeloma cell lines (HMCL), it was shown that serum and MGF cell starvation can downregulate these pathways Jourdan, et al 2000) . Of note, no genetic alterations antibodies and analysed with a FACScan flow cytometer using Cell Quest software (Becton Dickinson, Moutain View, CA, USA). The relative fractions of viable CD138 negative, CD138 and CD34 positive cells were determined and the number of cells calculated for each cell population.
Western blot analysis
HMCL were IL-6 starved for 3 hours in RPMI1640/ 2 % FCS, cultured with or without AS602868 (10 µM) for 30 minutes and then stimulated for 15 minutes with or without TNF-α (10 ng/ml). Cells were lysated in 10 mM Hepes (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% NP-40, 100 µM Na 3 VO 4 , 1mM DTT, 100 µg/ml Pefabloc, 20 mM ß-glycerophosphate, 10 mM p-nitrophenolphosphate (PNPP), 10 µg/mL aprotinin, 10 mM NaF, 1 µg/mL leupeptin, 0.5 mM PMSF and 0.5 µg/mL pepstatin. Aliquots containing 50 µg of total protein were resolved in 12% sodium dodecyl sulfatepolyacrylamide by gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany). Membranes were blocked for 2h at room temperature in 140 mM NaCl, 3 mM KCl, 25 mM Tris-HCl (pH 7.4), 0.1% tween 20 (TBS-T), 5% non-fat milk), then incubated for 1h at room temperature with primary antibodies. The primary antibodies were visualized with goat anti-mouse (Biorad SA, Yvry Sur Seine, France) peroxydase-conjugated antibodies (at 1:10 000 dilution in TBS-T) using an enhanced chemiluminescence detection system. The membranes were stripped twice with 100 mM Glycin (pH 2.2), 0.1% NP 40 and 1% SDS for 30 minutes at room temperature.
Real-time RT-PCR
Total RNA was converted to cDNA using the Superscript II reverse transcriptase (RT; Invitrogen, Cergy Pontoise, France). The assays-on-demand primers and probes and the TaqMan Universal Master Mix were used according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). Measurement of gene expression was performed using the ABI Prism 7000 Sequence Detection System. Quantitative PCR analysis was completed using ABI PRISM 7000 SDS Software. Ct values were collected for glyceraldehyde-3-phosphate deshydrogenase (GAPDH) and the genes of interest during log phase of the cycle. Gene of interest levels were normalized to GAPDH for each sample (δCt = Ct gene of interest -Ct GAPDH) and compared with the values obtained for a known positive control using the following formula 100/2 δδCt where δδCt = δCt unknown -δCt positive control.
Apoptotic cell detection assay
Apoptotic cells were detected by using fluorescein isothiocyanate-labeled annexin V (FITC-annexin-V, Boehringer Mannheim). Annexin V has a high affinity for phosphatidylserine present on the outer cytoplasmic membrane of apoptotic cells (Vermes, et al 1995) . Cells were washed, labelled with FITC-annexin-V according to the manufacturer's recommendations and analyzed with a FACScan flow cytometer using Cell Quest software (Becton Dickinson).
Cell cycle analysis
The cell cycle distribution of the cell lines was assessed by flow cytometry, using propidium iodide (PI) and bromodeoxyuridine (BrdU) 
Statistical analysis
Statistical comparisons were made with the non-parametric Mann-Whitney test or the Student t-test. The minimal level of significance was P < .05.
Results

AS602868 IKK2 inhibitor blocks NF-κB activation in human myeloma cell lines (HMCL).
In order to visualise the inhibitory effects of AS602868 on NF-κB activation in myeloma cells, two HMCL (XG-6 and XG-14) were first starved of IL-6 in low serum conditions to downregulate constitutive NF-κb activation, then stimulated with TNF-α. Phosphorylation of IκBα was assessed by Western blot analysis. As shown in Fig   1A , TNF-α induces a phosphorylation of IκBα in both HMCL which is completely abrogated by AS602868 IKK2 inhibitor. IL-6-induced STAT3 and ERK1/2 phosphorylation was not inhibited by AS602868 in either cell line (data not shown).
Using real-time quantitative RT-PCR, we show that TNF-α induced an upregulation in the expression of a panel of NF-κB-inducible genes in XG-6 and XG-14 cells and that AS602868 strongly inhibited the TNF-α effect (Fig 1B) .
AS602868 IKK2 inhibitor blocks the proliferation of human myeloma cell lines.
Effects of increasing concentrations of AS602868 IKK2 inhibitor on the proliferation of 12 IL-6-dependent and 2 autonomously growing myeloma cell lines were examined. 
AS602868 IKK2 inhibitor induces apoptosis and blocks cell cycle progression of HMCL.
To assess the effects of the IKK2 inhibitor on apoptosis and cell cycle of MM cells, the two cell lines determined to be the most sensitive to AS602868 (XG-3 and XG-12) were selected and cultured with graded inhibitor concentrations. We chose concentrations inducing 10, 50 or 90 % of growth inhibition of the cell line in a previous experiment. As indicated in Table 2 (Fig 3) .
AS602868 increases the cytotoxicity of melphalan or Velcade.
In order to investigate the effect of AS602868 association with melphalan or The survival of myeloma cells is strongly dependent of interactions with bone marrow environment (Gu, et al 2000) . In particular, myeloma cell adhesion to bone marrow stromal cells (BMSC) induces NF-κB-dependent up-regulation of transcription of IL-6 (a major myeloma growth factor) by BMSC (Chauhan, et al 1996) . Importantly, we show here that the AS602868 IKK2 inhibitor induces apoptosis in patients' primary myeloma cells that were cultured together with their bone marrow environment cells.
Our results indicate that hematopoietic progenitors (CD34+ cells) are targeted by AS602868. We may anticipate that treatment of patients with AS602868 will result in decreased hematopoietic cell counts, limiting the long term use of this inhibitor. It has been suggested that an increase in NF-κB activation could be responsible for tumor chemoresistance in MM, as in others cancers (Feinman, et al 1999; Ma, et al 2003; Mitsiades, et al 2002a; Wang, et al 1999) . Indeed, using NF-κB inhibitor could revert or delay the development of chemoresistance to conventional drugs. We show here that addition of suboptimal AS602868 IKK2 inhibitor concentrations increases the growth inhibition induced by two major therapeutic myeloma drugs, the melphalan alkylating agent and the proteasome inhibitor PS341 (Velcade). Velcade, as dexamethasone or thalidomide, was shown to induce apoptosis and growth inhibition of myeloma cells in part via the inhibition of constitutive activation of NF-κB (Feinman, et al 1999; Hideshima, et al 2002; Mitsiades, et al 2002b) . However, these drugs do not target NF-κB exclusively and their inhibitory effects cannot be totally attributed to the inhibition of NF-κB activation. Moreover, it is not clear if these drugs allow a complete or a partial and reversible inhibition of NF-κB activation. In the case of Velcade, this drug inhibits the NF-κB pathway by blocking IκB-α degradation, but this effect is not sufficient to explain its major antitumoral effects (Ma, et al 2003) .
Indeed, Velcade has also been shown to inhibit MAPK signalling of MM cells (Hideshima, et al 2001) and to induce proapoptotic/terminal unfolded protein response in tumoral cells (Obeng, et al 2006) . Our results suggest that AS602868
IKK2 inhibitor can improve a partial inhibition of NF-κB activation induced by Velcade and strengthen the idea that treatments using a combination of conventional drugs with a specific NF-κB inhibitor could present an advantage to inhibit the myeloma cell growth.
In conclusion, this study shows that a pharmacological inhibition of the constitutive activation of the NF-κB pathway can block HMCL and primary myeloma cells growth and, in combination with conventional therapy, might represent an innovative approach for treating MM patients. HMCL were IL-6-starved to reduce constitutive NF-κB activation and pre-treated with or without AS602868 as in (A) before stimulation with TNF-α (10 ng/ml) for one hour.
Legends to figures
The relative gene RNA level was determined as described in Materials and Methods.
The "1" value was assigned for each cell line to the control before pre-treatment with AS602868. HMCL were cultured as indicated in Fig 2 in and 90% inhibition of proliferation) were determined for each cell line. Results are the mean of at least two separate experiments. NR = not reached. Table 2 : AS602868 induces apoptosis and blockade of entry in the S phase of the cell cycle resulting in the inhibition of the cell growth of HMCL.
HMCL were cultured without (control culture medium) or with AS602868 IKK2 inhibitor (0.35, 1.68 and 6.14 µM for XG-3 and 0.24, 1.29 and 4.53 µM for XG-12).
These concentrations were those inducing 10%, 50% and 90% inhibition of the cell line proliferation in a previous experiment. The percentage of Annexin V + cells, of cells in the S phase of the cell cycle and the cell counts were assayed at day 3 of culture. Results are the mean ± SD of three separate experiments. Statistical analyses were carried out using a Student's t test for pairs. * Significantly higher or lower values than control (P < .05); ** significantly higher or lower values than control (P < .01).
AS602868 IKK2 inhibitor Co 0.35 µM 1.68 µM 6.14 µM XG-3 Annexin V % 23.6 ± 3.3 25.4 ± 2.9 31.0 ± 0.6 * 55.8 ± 11.1 * S phase % 37.5 ± 6.1 34.7 ± 6.3 30.2 ± 6.1 ** 16.6 ± 6.1 ** Cell count x10 6 /ml 0.60 ± 0.16 0.53 ± 0.11 0.40 ± 0.06 * 0.20 ± 0.07 * Co 0.24 µM 1.29 µM 4.53 µM XG-12 Annexin V % 22.5 ± 5.1 22.7 ± 1.0 32.3 ± 7.2 ** 70.0 ± 9.5 ** S phase % 40.2 ± 0.7 38.1 ± 1.4 36.4 ± 1.9 * 20.0 ± 7.6 ** Cell count x10 6 /ml 0.57 ± 0.17 0.57 ± 0.11 0.43 ± 0.10 0.19 ± 0.07 * Figure 1 
